TAK-242 in Patients With Acute Alcoholic Hepatitis
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
A phase 2a double-blind, randomized, placebo-controlled, multicenter, proof-of-concept study
to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of TAK-242 in
subjects with acute decompensation of alcohol-related cirrhosis due to alcoholic hepatitis
resulting in acute-on-chronic liver failure.